Pelthos Therapeutics (PTHS) Stock Analysis

What Pelthos Therapeutics does

Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.

Key metrics

ETFs linked to PTHS

Broad-market and Healthcare sector ETFs an investor holding Pelthos Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PTHS fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Pelthos Therapeutics?

Pelthos Therapeutics trades under the ticker PTHS on AMEX.

Which exchange is PTHS listed on?

PTHS is listed on AMEX.

What sector does Pelthos Therapeutics operate in?

Pelthos Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PTHS in a portfolio?

PortView shows PTHS's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.